[1]王东平,苏爱美,韩欣怡.12种抗生素组合对耐碳青霉烯类鲍曼不动杆菌联合药敏试验[J].现代检验医学杂志,2025,40(02):64-69.[doi:10.3969/j.issn.1671-7414.2025.02.012]
　WANG Dongping,SU Aimei,HAN Xinyi.Comined Antimicrobial Susceptibility Test of 12 Antibiotic Combinations Against Carbapenem-resistant Acinetobacter Baumannii[J].Journal of Modern Laboratory Medicine,2025,40(02):64-69.[doi:10.3969/j.issn.1671-7414.2025.02.012]
点击复制

12种抗生素组合对耐碳青霉烯类鲍曼不动杆菌联合药敏试验()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年02期
页码:
64-69
栏目:
论著
出版日期:
2025-03-15

文章信息/Info

Title:
Comined Antimicrobial Susceptibility Test of 12 Antibiotic Combinations Against Carbapenem-resistant Acinetobacter Baumannii
文章编号:
1671-7414（2025）02-064-06
作者:
王东平; 苏爱美; 韩欣怡
（青岛市第八人民医院检验科，山东青岛 266100）
Author(s):
WANG Dongping; SU Aimei; HAN Xinyi
（Department of Clinnical Laboratory，Qingdao Eighth People’s Hospital，Shandong Qingdao 266100，China）
关键词:
耐碳青霉烯类鲍曼不动杆菌; 棋盘法; 联合药敏试验; 部分抑菌浓度指数
分类号:
R378.2；R446.5
DOI:
10.3969/j.issn.1671-7414.2025.02.012
文献标志码:
A
摘要:
目的 观察黏菌素（COL）分别联合替加环素（TGC）、头孢哌酮/ 舒巴坦（SCF）、氨苄西林/ 舒巴坦（SAM）、美罗培南（MEM）、阿米卡星（AK）和左氧氟沙星（LEV），TGC 分别联合SCF，SAM，MEM 和AK，SCF 分别联合MEM 和AK 对耐碳青霉烯类鲍曼不动杆菌（CRAB）体外联合药物敏感性，筛选有效的抗感染治疗方案。方法 收集2023 年1 ～ 12 月青岛市第八人民医院临床标本中分离的非重复CRAB 58 株，采用微量肉汤稀释法测定抗生素对菌株的最低抑菌浓度（MIC），棋盘法进行联合药敏试验，计算部分抑菌浓度指数（FIC）判定联合效果。结果 COL+SCF协同率为70.69%，协同率与相加率之和为96.55%。COL+TGC，COL+SAM，COL+MEM，COL+AK，COL+LEV，TGC+SCF，TGC+SAM，TGC+MEM，TGC+AK，SCF+MEM 及SCF+AK 协同率分别为 34.48%，65.52%，51.72%，37.93%，22.42%，27.59%，27.59%，37.93%，41.38%，48.28% 和25.86%； 协同率与相加率之和分别为77.58%，91.38%，84.48%，65.52%，39.66%，67.25%，62.07%，58.62%，55.17%，82.76% 和74.14%。12 种药物联合方案对CRAB 菌株的MIC 范围，MIC50 和MIC90 值与各个单药相比均有不同程度的减低，所有组合均未出现拮抗作用。结论COL+SCF 的协同率与相加率之和最高，COL+LEV 协同率与相加率之和最低，可作为临床经验用药参考。
Abstract:
Objective To observe the in vitro susceptibility test result of colistin (COL) combined with tigecycline (TGC)， cefoperazone/sulbactam (SCF)， ampicillin/sulbactam (SAM)， meropenem (MEM)， amikacin (AK) and levofloxacin (LEV)， TGC combined with MEM, SCF, SAM and AK，SCF combined with MEM， AK to carbapenem-resistant Acinetobacter baumannii (CRAB), and screen the effective anti-infective therapy. Methods 58 CRAB strains were isolated from clinic specimens from Qingdao Eighth People’s Hospital from January 2023 to December 2023. The minimal inhibitory concentration (MIC) of antimicrobial agents against CRAB strains was determined by the micro broth dilution method. A combined antimicrobial susceptibility test was performed by the chessboard dilution method. The fractional inhibitory concentration (FIC) index was calculated to determine the combined effect. Results The synergistic rates of COL and SCF was 70.69%, and the sum of synergistic rates and additive rates was 96.55%. The synergistic rates of COL and TGC, COL and SAM, COL and MEM, COL and AK, COL and LEV, TGC and SCF, TGC and SAM, TGC and MEM, TGC and AK, SCF and MEM, SCF and AK were 34.48%, 65.52%, 51.72%, 37.93%, 22.42%, 27.59%, 27.59%, 37.93%, 41.38%, 48.28% and 25.86%, and the sum of synergistic rates and additive rates were 77.58%, 91.38%, 84.48%, 65.52%, 39.66%, 67.25%, 62.07%, 58.62%, 55.17%, 82.76% and 74.14%, respectively. The range, MIC50 and MIC90 of 12 combination regimens for CRAB strains were decreased to some extent compared with those of each single drug. No antagonism effect was observed for all the combinations. Conclusion The sum of synergy rate and addition rate of COL combined with SCF is the highest, and the sum of synergy rate and addition rate of COL combined with LEV is the lowest, which could provide reference for clinical experience medication.

参考文献/References:

[1] 雷康璠, 吴松, 张文轩. 抗鲍曼不动杆菌药物研究进展[J]. 药学学报,2023,58(12):3583-3598. LEI Kangfan, WU Song, ZHANG Wenxuan.Research progress of anti-Acinetobacter baumanni drug [J].Acta Pharmaceutica Sinica, 2023, 58(12): 3583-3598.
[2] BRINK A J. Epidemiology of carbapenem-resistant Gram-negative infections globally[J]. Current Opinion in Infectious Diseases, 2019, 32(6): 609-616.
[3] 全国细菌耐药监测网. 2022 年全国细菌耐药监测报告( 简要版) [EB/OL].(2023-11-20)https://www.carss.cn/Report/Details?aId=917. China Antimicrobial Resistance Surveillance System. 2022 China antimicrobial resistance surveillance system report (abridged edition) [EB/OL](. 2023-11-20) https://www.carss.cn/Report/Details?aId=917.
[4] ABDUL-MUTAKABBIR J C, YIM J, NGUYEN L, et al. In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-Resistant Acinetobacter baumannii[J]. Antibiotics-Basel, 2021, 10(7): 880.
[5] Clinical and Laboratory Standards Institute. CLSI M100:Performance standards for antimicrobial susceptibility testing. 33th ed [S]. Wayne:PA, CLSI M100,2023.
[6] 欧洲临床微生物和感染病学会药敏委员会华人抗菌药物敏感性试验委员会, 中国医药教育协会感染疾病专业委员会. 多黏菌素药物敏感性检测及临床解读专家共识[J]. 协和医学杂志,2020,11(5):559-570. Chinese Committee on Antimicrobial Susceptibility Testing,European Committee on Antimicrobial Susceptibility Testing,European Society of Clinical Microbiology and Infectious Diseases,Expert Committee on Infectious Diseases,China Medical Education Association. Expert consensus on polymyxin antimicrobial susceptibility testing and clinical interpretation[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 559-570.
[7] U.S. Food and Drug Administration. Tigecycline-Injection Products:FDA-identified interpretive criteria[EB/OL]. [2023-01-26]. https://www.fda.gov/drugs/development-resources/tigecycline-injectionproducts.
[8] 陆国平, 唐浩, 夏兆新, 等.11 种联合方案对耐碳青霉烯类肠杆菌的体外联合药敏试验[J]. 中国感染控制杂志,2023,22(3):287-294. LU Guoping, TANG Hao, XIA Zhaoxin, et al. In vitro combined antimicrobial susceptibility test of 11 combined regimens against carbapenem-resistant Enterobacterales [J]. Chinese Journal of Infection Control,2023,22(3): 287-294.
[9] 汪复, 张婴元. 实用抗感染治疗学[M].3 版. 北京:人民卫生出版社,2020. WANG Fu, ZHANG Yingyuan. Practical anti infective therapy [M].3rd Ed.Beijing:People’s Health Publishing House,2020.
[10] 游铠旭, 魏星, 徐革. 青霉素结合蛋白3 编码基因FtsI在多重耐药鲍曼不动杆菌中表达及碳青霉烯类诱导对其表达的影响[J]. 现代检验医学杂志,2022,37 (3):47-52. YOU Kaixu,WEI Xing,XU Ge. Expression of penicillinbinding protein 3 encoding gene FtsI in multidrug-resistant Acinetobacter baumannii and the effect of carbapenems induction on its expression[J].Journal of Modern Laboratory Medicine,2022, 37(3):47-52.
[11] SEIFERT H,BLONDEAU J,LUCA?EN K,et al. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018) [J]. Journal of Global Antimicrobial Resistance, 2022, 31: 82-89.
[12] KARLOWSKY J A, HACKEL M A, MCLEOD S M, et al. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumanniicalcoaceticus complex collected from 2016 to 2021[J].Antimicrobial Agents and Chemotherapy, 2022, 66(9): e0078122.
[13] MORRISSEY I, OLESKY M, HAWSER S, et al. In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017[J]. Antimicrobial Agents and Chemotherapy, 2020, 64(3): e01699-19.
[14] 赵玉杰, 秦玲, 吴巧萍, 等. 多黏菌素B 异质性耐药鲍曼不动杆菌的体外联合药敏研究[J]. 中国卫生检验杂志,2023,33(4):397-400. ZHAO Yujie, QIN Ling, WU Qiaoping, et al. A study on combined in vitro drug sensitivity test of polymyxin-B heteroresistant Acinetobacter baumannii [J]. Chinese Journal of Health Laboratory Technology, 2023, 33(4): 397-400.
[15] 胡永煜, 吴湜, 郑永贵, 等. 头孢哌酮- 舒巴坦联合黏菌素等6 种抗菌药物对碳青霉烯类耐药鲍曼不动杆菌体外抗菌作用研究[J]. 中国感染与化疗杂志,2022,22(2):189-193. HU Yongyu, WU Shi, ZHENG Yonggui, et al. In vitro synergistic antimicrobial activity of cefoperazonesulbactam combined with other six antimicrobial agents against carbapenem-resistant Acinetobacter baumannii[J]. Chinese Journal of Infection and Chemotherapy,2022,22(2): 189-193.
[16] BIAN Xingchen, LIU Xiaofen, FENG Meiqing, et al. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii[J]. International Journal of Antimicrobial Agents, 2021, 57(2): 106271.
[17] TAMMA P D, AITKEN S L, BONOMO R A, et al. Infectious diseases society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections[J]. Clinical Infectious Diseases, 2022, 74(12): 2089-2114.
[18] 李阳昱, 杨旭, 陈孝红, 等. 耐碳青霉烯类肺炎克雷伯菌的耐药机制和治疗策略研究进展[J]. 现代检验医学杂志,2023,38(6):191-199. LI Yangyu, YANG Xu, CHEN Xiaohong, et al. Research progress on resistance mechanisms and therapy strategies of carbapenem resistant Klebsiella pneumonia [J]. Journal of Modern Laboratory Medicine, 2023, 38(6): 191-199.
[19] 中国医药教育协会感染疾病专业委员会, 中华医学会呼吸病学分会, 中华医学会重症医学分会, 等. 中国多黏菌素类抗菌药物临床合理应用多学科专家共识[J]. 中华结核和呼吸杂志,2021,44(4):292-310. Infectious Diseases Society of China,Chinese Thoracic Society,Chinese Society of Critical Care Medicine,et al. Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China [J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2021, 44(4): 292-310.
[20] 张思琴, 卢鸿, 曹建明, 等. 体外联合用药对黏菌素异质性耐药鲍曼不动杆菌的抗菌活性研究[J]. 中华微生物学和免疫学杂志,2018,38(8):593-598. ZHANG Siqin, LU Hong, CAO Jianming, et al. In vitro antibiotic effects of drug combinations against colistinheteroresistant Acinetobacter baumannii[J]. Chinese Journal of Microbiology and Immunology, 2018, 38(8): 593-598.
[21] 叶卓幸, 汤燕君, 何璐茜, 等. 四环素类抗生素耐药研究进展: 质粒介导的替加环素耐药机制[J]. 生态毒理学报,2022,17(4):122-140. YE Zhuoxing, TANG Yanjun, HE Luqian, et al. Mechanisms of tetracycline resistance:plasmidmediated tigecycline resistance[J]. Asian Journal of Ecotoxicology, 2022, 17(4): 122-140.
[22] PAUL M, CARRARA E, RETAMAR P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)[J]. Clinical Microbiology and Infection, 2022, 28(4): 521-547.
[23] DENG Yanling, CHEN Lin, YUE Mingrui, et al. Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia[J]. BMC Infectious Diseases, 2022, 22(1): 795.
[24] 任俊丽, 彭芳辰, 周煊平, 等. 替加环素不同联合治疗方案治疗耐碳青霉烯鲍氏不动杆菌肺部感染的临床疗效及安全性[J]. 中华医院感染学杂志,2024,34(1):18-22. REN Junli, PENG Fangchen, ZHOU Xuanping, et al. Clinical safety and effects of tigecycline combinations on treatment patients with carbapenem-resistant Acinetobacter baumannii pulmonary infection[J].Chinese Journal of Nosocomiology, 2024, 34(1): 18-22.
[25] 肖园园, 谭彩霞, 李春辉, 等( 编译). 美国感染病学会关于产超广谱β- 内酰胺酶肠杆菌目细菌(ESBL-E)?耐碳青霉烯类肠杆菌目细菌(CRE)?难治性耐药铜绿假单胞菌(DTR-PA)?产Amp C β- 内酰胺酶肠杆菌目细菌(AmpC-E)?耐碳青霉烯类鲍曼不动杆菌(CRAB) 和嗜麦芽窄食单胞菌的抗感染治疗指引(2022 版) 摘要[J]. 中国感染控制杂志,2022,21(12):1267-1276. XIAO Yuanyuan, TAN Caixia, LI Chunhui, et al. Summary of infectious diseases society of America guidance on the treatment of extended-spectrum β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales,Pseudomonas aeruginosa with difficult-to-treat resistance,Amp C β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii,and Stenotrophomonas maltophilia infections(2022 edition) [J]. Chinese Journal of Infection Control, 2022, 21(12): 1267-1276.
[26] 丁丽, 陈佰义, 李敏, 等. 碳青霉烯类耐药革兰阴性菌联合药敏试验及报告专家共识[J]. 中国感染与化疗杂志,2023,23(1):80-90. DING Li, CHEN Baiyi, LI Min, et al. Expert consensus on antimicrobial synergy testing and reporting of carbapenemresistant gram-negative bacteria[J]. Chinese Journal of Infection and Chemotherapy, 2023, 23(1): 80-90.

相似文献/References:

[1]陆丹倩,芮勇宇,杨秋,等.耐碳青霉烯类鲍曼不动杆菌基因检测及同源性分析[J].现代检验医学杂志,2016,31(06):62.[doi:10.3969/j.issn.1671-7414.2016.06.017]
　LU Dan-qian,RUI Yong-yu,YANG Qiu,et al.Gene Detection and Homology Analysis of Acinetobacter-Resistant Acinetobacter Baumannii[J].Journal of Modern Laboratory Medicine,2016,31(02):62.[doi:10.3969/j.issn.1671-7414.2016.06.017]

备注/Memo

备注/Memo:
作者简介：王东平（1987-），女，硕士，主管技师，研究方向：病原生物学检测，E-mial:wdp19870628@126.com。
通讯作者：苏爱美（1979-），女，硕士，副主任技师，研究方向：病原生物学检测，E-mail:lwsuaimei@126.com。
更新日期/Last Update: 2025-03-15